Clinical Trials Browser

Has results × Colonic Neoplasms × Panitumumab × Clear all

Colonic Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01814501 2025-02-05

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Phase 2 Completed

16 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Phase 1/2 Completed

177 enrolled 31 charts

Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Phase 2 Active not recruiting

12 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00819780 2022-12-06

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Phase 2 Completed

285 enrolled 31 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00089635 2022-11-07

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

203 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 Completed

1,010 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00940316 2019-05-07

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Phase 2 Completed

28 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00418938 2018-10-17

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Phase 2 Completed

266 enrolled 17 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00332163 2016-02-23

STEPP

Phase 2 Completed

95 enrolled 23 charts

Gastrointestinal

Colonic Neoplasms, Exanthema, Rectal Neoplasms, Colorectal Neoplasms

NCT00411450 2016-02-15

PRECEPT

Phase 2 Completed

116 enrolled 20 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00630786 2014-02-06

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Phase 1/2 Completed

53 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Clinical Trials

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

STEPP

PRECEPT

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study